HOTH News and Press, Hoth Therapeutics Inc. From 03/09/21

ACADIA Pharmaceuticals (ACAD) -45% after suffers setback in label expansion application for Pimavanserin.Stitch Fix (SFIX) -22% on FQ2 earnings release.Waitr Holdings (WTRH) -16% on Q4 earnings release.DICK'S Sporting Goods (DKS) -6% on Q4 earnings rele...

Hoth Therapeutics (HOTH) inks securities purchase agreement with institutional investors to raise capital through issuance of an ~7.59M common shares at $1.975/share, in a private placement priced at-the-market.Additionally, warrants to purchase of ~7.59M shares at exercise price of $1.8...

Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire NEW YORK , March 8, 2021 /PRNewswire/ --  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today...

Hoth Therapeutics (HOTH) provides an update on preclinical study on HT-002 for the prevention and/or treatment of Sars-CoV-2, or COVID-19. There are three leading peptide candidates that have been optimized chemically to maximize the potential viral inhibition.One of the peptide candidates ha...

Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies Analysis supports that these optimized peptides could be effective against the emerging UK and South African SARS-CoV-2 strain variants PR Newswire NEW YORK , Mar...

Hoth Therapeutics ([[HOTH]] +0.9%) announces that it has completed recruitment of cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.The company hopes to report preliminary results from the study la...

Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis PR Newswire NEW YORK , March 1, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company...

Hoth Therapeutics (HOTH) expands its licensing agreement from North Carolina State University to include the worldwide development and commercialization of treatments targeting mast cell derived cancers and anaphylaxis. The HT-KIT drug is designed to more specifically target th...

Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment PR Newswire NEW YORK , Feb. 26, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company , today announced it has exp...

Hoth Therapeutics Retains RedChip to Increase Investor Awareness PR Newswire NEW YORK , Feb. 25, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company , today announced it retained RedChip Companies, Inc. ("RedChip...